{
    "clinical_study": {
        "@rank": "94340", 
        "brief_summary": {
            "textblock": "RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause\n      less damage to normal tissue.\n\n      PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating\n      patients who have liver metastases, lung metastases, or other advanced solid tumors."
        }, 
        "brief_title": "Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors", 
        "completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Metastatic Cancer", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the feasibility of fractionated stereotactic body radiosurgery in patients\n           with advanced extracranial tumors.\n\n        -  Assess the toxicities of this treatment regimen in these patients.\n\n        -  Determine tumor response and cause of death in these patients treated with this\n           regimen.\n\n      OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for\n      5-10 days for a total of 3 treatments.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed malignancy\n\n               -  Extracranial recurrent or metastatic disease or primary tumor not predicted to\n                  be controlled with standard radiotherapy\n\n               -  Incurable with any standard therapy\n\n          -  No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or\n             heart)\n\n          -  Tumor visible by CT scan\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin less than 2.0 times upper limit of normal (ULN)\n\n          -  AST and ALT less than 5 times ULN\n\n        Renal:\n\n          -  Creatinine less than 2.0 mg/dL\n\n        Pulmonary:\n\n          -  FEV1 greater than 0.75 L\n\n        Other:\n\n          -  No unsuitable size or geometric proportion that would preclude stereotactic\n             immobilization\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 14 days since prior anticancer biologic therapy and recovered\n\n        Chemotherapy:\n\n          -  At least 14 days since prior anticancer chemotherapy and recovered\n\n        Endocrine therapy:\n\n          -  At least 14 days since prior anticancer endocrine therapy and recovered\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 14 days since prior anticancer radiotherapy and recovered\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006456", 
            "org_study_id": "CDR0000068151", 
            "secondary_id": [
                "P30CA016059", 
                "MCV-MCC-9812-2C", 
                "NCI-V00-1612"
            ]
        }, 
        "intervention": {
            "intervention_name": "stereotactic radiosurgery", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "unspecified adult solid tumor, protocol specific", 
            "lung metastases", 
            "liver metastases"
        ], 
        "lastchanged_date": "February 23, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MCV-MCC-9812-2C"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298-0058"
                }, 
                "name": "Massey Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors", 
        "overall_official": {
            "affiliation": "Massey Cancer Center", 
            "last_name": "Danny Y. Song, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006456"
        }, 
        "responsible_party": {
            "name_title": "Danny Song, MD", 
            "organization": "Virginia Commonwealth University/Massey Cancer Center"
        }, 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1999", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2010"
    }, 
    "geocoordinates": {
        "Massey Cancer Center": "37.541 -77.436"
    }
}